No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 61.6x · 10Y median 23.0x · 93rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2023-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2024-02-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2023-08-03. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2023-05-04.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2023-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2024-02-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:00:58.263Z. Latest historical point 2023-08-03. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for AbCellera Biologics Inc. (ABCL) stock was $13.35 as of Oct 6, 2026, 1:00 PM EDT, down 3.12% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +132.6% · 3-year avg +46.1%/yr · 5-year avg -3.6%/yr
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies.
Biotechnology · Vancouver, BC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.18
Revenue Est.
$6.21M
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.17
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ABCL | $4.08B | $13.35 | -3.12% | +132.62% | -3.57% | N/A | N/A |
| 2RLAY | $4.02B | $18.36 | -5.29% | +251.71% | -7.92% | N/A | vs ABCL |
| 3LIVN | $4.15B | $75.50 | -1.21% | +42.96% | -1.66% | +2.48% | vs ABCL |
| 4ICUI | $3.96B | $158.57 | -1.75% | +32.04% | -7.18% | +2.51% | vs ABCL |
| 5EWTX | $4.28B | $39.78 | -1.29% | +156.35% | +16.95% | N/A | vs ABCL |
| 6INDV | $4.40B | $35.27 | -2.01% | +55.00% | +19.65% | +6.16% | vs ABCL |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$4.05M
vs Estimate
$7.85M
Consensus Rating
Based on 10 analysts
Average Price Target
$16.70
+25.1% upside
Low
$9.00
Current
$13.35
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.19 | $-0.17 | $-0.16 | 4 |
| Quarter ending Dec 2026 | $-0.36 | $-0.27 | $-0.18 | 4 |
| Quarter ending Mar 2027 | $-0.38 | $-0.19 | $-0.05 | 1 |
| Quarter ending Jun 2027 | $-0.39 | $-0.20 | $-0.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.70 | $-0.67 | $-0.63 | 6 |
| FY 2027 | $-0.77 | $-0.74 | $-0.65 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.97M | $6.21M | $7.66M | 7 |
| Quarter ending Dec 2026 | $3.28M | $6.98M | $8.58M | 7 |
| Quarter ending Mar 2027 | $4.38M | $9.80M | $17.52M | 3 |
| Quarter ending Jun 2027 | $4.39M | $9.84M | $17.58M | 3 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $19.13M | $26.29M | $31.91M | 8 |
| FY 2027 | $9.08M | $28.37M | $41.01M | 7 |
